Focal cortical dysplasia (FCD) type 2 is a congenital malformation of the cerebral cortex that is often associated with ...

At its core, diabetes mellitus is about your body’s relationship with insulin, the hormone responsible for helping cells ...

Nurix is eligible for an additional $420 million in development, regulatory and commercial milestones associated with the ...

FDA clears Nurix Therapeutics, Inc.'s GS-6791 for inflammatory disorders; Nurix earns $5M milestone from Gilead. Click for my ...

Sol-Gel to receive $16 million during 2025Cash runway is expected to extend into the first quarter of 2027; Company expects to have sufficient cash to complete its Phase III clinical trialSGT-610 ...

Nigel McCracken, chief operating officer, Virax Biolabs, discusses new findings that reveal altered cytokine activity and ...

Nurix Therapeutics (NRIX) announced that the U.S. Food and Drug Administration, FDA, has cleared the IND for the IRAK4 degrader ...

DelveInsight's "FYARRO Market Size, Forecast, and Market Insight Report" highlights the details around FYARRO, an mTOR inhibitor. The report provides product descriptions, patent details, and ...

Sol-Gel Technologies (SLGL) entered into a product purchase agreement with a subsidiary of Mayne Pharma Group (MAYNF) for the sale and ...

A groundbreaking study published in the journal Current Neuropharmacology highlights a concerning potential link between ...

Cleft lip and cleft palate are among the most common birth defects, occurring in about one in 1,050 births in the United ...

Cleft lip and cleft palate are among the most common birth defects, occurring in about one in 1,050 births in the United States.